Gliosarcoma
MONDO:0016681A rare histological variant of glioblastoma (WHO grade IV) characterized by a biphasic tissue pattern with alternating areas displaying glial and mesenchymal differentiation (WHO).
Also known as: glioblastoma with a sarcomatous component, gliosarcoma, sarcomatous glioblastoma
2946 clinical trials for this condition and its sub-types, 65 tagged with Gliosarcoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
-
Hormone therapy explored for aggressive brain tumor
Disease control Stopped earlyThis early-phase study tested whether natural progesterone, a hormone normally involved in pregnancy, could help control recurrent glioblastoma (a fast-growing brain cancer). Four adults whose cancer had returned after standard treatments received daily progesterone injections un…
Early phase 1 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Experimental brain tumor combo shows promise but trial halted early
Disease control Stopped earlyThis study tested a new drug called zotiraciclib (TG02) combined with the standard chemotherapy temozolomide in adults with recurrent anaplastic astrocytoma or glioblastoma. The goal was to find the safest dose and see if the combination worked better than temozolomide alone. The…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Experimental virus gets a second shot at brain tumors
Disease control Stopped earlyThis study tested the safety of giving a second dose of an experimental virus (C134) directly into the brain tumor of patients whose malignant glioma had returned. Only one patient was enrolled before the study was stopped. The goal was to see if repeat dosing was safe and tolera…
Phase 1 • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Experimental drug navtemadlin tested for glioblastoma
Disease control Stopped earlyThis early-phase trial tested the drug navtemadlin in 32 adults with glioblastoma, a type of brain cancer. The study aimed to find the best dose and check side effects, both for newly diagnosed and recurrent cases. The trial was terminated early, so results are limited.
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Brain cancer drug trial halted after just two patients
Disease control Stopped earlyThis study tested a new drug called VAL-083 in people with glioblastoma, an aggressive brain cancer that had returned after standard treatments. The trial aimed to see if VAL-083 could help patients live longer. However, the study was stopped early after only 2 people enrolled, s…
Phase 3 • Sponsor: DelMar Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 26, 2026 13:46 UTC